Illumina, Inc. (NASDAQ:ILMN) announced today that the United States Patent and Trademark office has ordered the re-examination of U.S. Patent Nos. 6,355,432 and 6,646,243.(original article)

It’s good news that we are living longer, but bad news that the longer we live, the better our odds of developing late-onset Alzheimer’s disease.(original article)

Over the course of the 20th Century, doctors waged war against infectious bacterial illness with the best new weapon they had: antibiotics.(original article)

Researchers at Cedars-Sinai Medical Center’s Department of Psychiatry and Behavioral Neurosciences are seeking participants for a clinical trial examining whether two polyunsaturated Omega-3 fatty acids are effective treatments for depression.The two fatty acids being studied — docosahexanoic acid (DHA) and eicosapentanoic acid (EPA) — are found naturally in fish oil, flaxseed and walnuts. Previous studies have indicated that nutritional supplements that contain Omega-3 fatty acids can be an effective treatment for depression, but this is the first to systematically test the two specific fatty acids against each other and against placebo in a large sample of people with major depression. DHA and EPA have anti-inflammatory properties and help stabilize brain cell membranes, both of which play a role in mood regulation.

The National Institutes of Health (NIH)-sponsored study, held in collaboration with Massachusetts General Hospital, will recruit a total of 300 adults ages 18-80 who are experiencing significant symptoms of major depressive disorder and are in good health. The five-year study is designed to test the safety, effectiveness and tolerability of DHA and EPA against each other and a placebo. Participants will receive one of the two drugs or a placebo for eight weeks in a randomized, double-blind manner.

Major depression affects at least 15 percent of the adult population. Unlike normal emotional experiences of sadness, loss or passing mood states, major depression is persistent and can significantly interfere with an individual’s thoughts, behavior and physical health. While it can be effectively treated, it is a leading cause of disability in the U.S. and in many other countries.

The Cedars-Sinai team, lead by principal investigator and department chair Mark Hyman Rapaport, M.D., will examine the effect of the therapies on participants’ symptoms, quality of life and psychosocial function. They will also examine how fatty acids in the blood and proteins involved in immune function are affected by Omega-3s. Participants will receive free and confidential evaluation and treatment as part of the study. No healthcare insurance is required. A comprehensive medical evaluation — including physical examination, laboratory tests and EKG — may be provided at no charge.

“The reported side effects of Omega-3 treatments have been mild and include upset stomach and a fishy taste in the mouth. There do not appear to be risks to the liver or adverse interactions with most other medications,” said Rapaport, though he added that people who have bleeding disorders or who are taking blood thinners should not use Omega-3 fatty acids. Check with your doctor first.

For more information on the study, call 1-888-CEDARS3.

Adapted from materials provided by Cedars-Sinai Medical Center.

Over the course of the 20th Century, doctors waged war against infectious bacterial illness with the best new weapon they had: antibiotics.(original article)

Severe muscle weakness caused by myasthenia gravis - a highly debilitating autoimmune disorder - can be prevented or reversed by blocking a key step in the immune response that brings on the disease, researchers at the Saint Louis University School of Medicine have found.(original article)

On 13th December 2007 a revised version of the European Patent Convention (EPC) came into force. This new law, known as EPC2000, has a number of consequences for the pharmaceutical industry and the way in which patent applications are examined.(original article)

Mesothelioma represents less than 1 percent of all cancers. It is rarely seen in smaller medical centers, where on average, a physician may see two cases in her/his career. At Mayo Clinic, three to four new cases are seen every month. Diagnosis and treatment of this cancer can be difficult, and proper management of the disease often includes evaluation at large medical centers by specialists more experienced in standard and experimental treatments for the disease.

Physicians from all over the world refer patients with mesothelioma to Mayo Clinic. Mayo’s strength lies in the ability to quickly assemble a team of experts from several areas, such as pulmonary medicine, thoracic surgery, oncology (cancer), radiation therapy and pathology who work with the patient to obtain a diagnosis and develop a treatment plan — usually within a few days.

Diagnosis

Diagnosing mesothelioma is often difficult because the symptoms are similar to those of numerous other conditions. Mayo Clinic has an experienced staff and the latest technologies for making an accurate diagnosis. Read more about diagnosis.

Treatment Options

Treatment for mesothelioma depends on the location of the cancer, the stage of the disease, and the patient’s age and general health. Standard treatment options include surgery, radiation therapy and chemotherapy, or a combination of these treatments. At Mayo Clinic experimental treatments are also available for patients who meet the requirements. Read more about treatment options.

What is Mesothelioma? Mesothelioma from the (Greek meso+ thelioma, tumor of middle lining tissue) is an uncommon cancer, originating from the cells which form the membrane lining the abdominal cavity (peritoneal membrane or peritoneum) which houses the intestines, or the chest (pleural membrane or pleura) cavity housing the heart and lungs, in which the cells making up those tissues begin to grow out of control.

Mesotheliomas most often are seen in older patients, more often men that have a history of occupational exposure to asbestos, although other causes such as radiation and certain viruses have occasionally been implicated. In a proportion of cases, no asbestos exposure can be identified.

Mesotheliomas involving the lung and pleura characteristically present as progressive shortness of breath due to the thickening of the lining membrane of the lung with gradual contraction of the breathing space; often, fluid accumulates in the lung spaces as well, further interfering with breathing, Mesotheliomas involving the abdominal cavity present with digestive symptoms, and abdominal swelling due to thickening of the lining membranes of the gut, and accumulation of large amounts of fluid in the abdomen.

How serious is it ? Mesotheliomas are serious and potentially life-threatening. Survival of patients with mesothelioma is usually short if effective treatment is not found, especially those with tumors that can be shown to be growing aggressively. Because mesotheliomas have usually spread throughout the pleural or peritoneal cavity before the diagnosis is made, complete surgical removal is only rarely possible. Moreover, mesotheliomas are not as sensitive to radiation therapy or chemotherapy as are many other tumors.

How are mesotheliomas diagnosed? In all cases, the diagnosis of mesothelioma must first be unquestionably established by biopsy of affected or suspicious tissues, and by definitive microscopic examination by a trained pathologist. Biopsy almost always requires an invasive procedure such as thoracoscopy and pleural biopsy, or laparotomy or laparoscopy, The removed tissues may be treated with special biological or chemical stains which are used to help the pathologist establish a firm diagnosis. The pathologist usually also comments upon the rate of growth and biological virulence of the tumor

Second, the tumor must be staged if possible by X-ray, CAT scan, MRI or other types of scans to clarify its location within the body, and to estimate the likelihood of effective curative or palliative therapy. Staging of mesothelioma by x-ray measurements, however, is difficult and often unreliable.

How are mesotheliomas treated? A treatment plan is devised depending upon the mesothelioma type, aggressiveness, primary location, and degree of local (rarely, distant) spread. The treatment of pleural mesothelioma is difficult. Treatment with surgery, radiation therapy or chemotherapy used alone or in combination may be proposed, depending upon the potential benefits and risks of each modality. Surgery is rarely used alone, but sometimes suffices when only a small pleural patch of mesothelioma is detected, thus allowing visually complete removal of the tumor. More often, mesotheliomas of the left or right pleural cavity cannot be completely removed without taking the entire lung (pneumonectomy) on the same side as well. In such cases, radiation therapy and/or chemotherapy is given postoperatively to help eradicate any residual mesothelioma that may have escaped the surgeon.

The treatment of peritoneal mesotheliomas is even more problematic; until recently no consistent treatment was available. At our institution, peritoneal mesotheliomas have been managed in the experimental setting with combined modality treatment consisting of extensive (usually not complete) debulking surgery, followed by intraperitoneal and systemic chemotherapy followed in turn by whole abdominal radiation therapy.

Because mesotheliomas now represent less than one percent of cancers and and are infrequently seen in the practice of most community oncologists, finding the correct treatment can be very difficult. Proper management of mesotheliomas often requires evaluation at larger tertiary hospitals or Comprehensive Cancer Centers by specialists in medical, surgical and radiation oncology with experience in all aspects of the clinical care of mesothelioma patients, including the newest experimental treatments.

Mesothelioma is a rare form of cancer in which malignant (cancerous) cells are found in the mesothelium, a protective sac that covers most of the body’s internal organs. Most people who develop mesothelioma have worked on jobs where they inhaled asbestos particles.

1. What is the mesothelium?

The mesothelium is a membrane that covers and protects most of the internal organs of the body. It is composed of two layers of cells: One layer immediately surrounds the organ; the other forms a sac around it. The mesothelium produces a lubricating fluid that is released between these layers, allowing moving organs (such as the beating heart and the expanding and contracting lungs) to glide easily against adjacent structures.

The mesothelium has different names, depending on its location in the body. The peritoneum is the mesothelial tissue that covers most of the organs in the abdominal cavity. The pleura is the membrane that surrounds the lungs and lines the wall of the chest cavity. The pericardium covers and protects the heart. The mesothelial tissue surrounding the male internal reproductive organs is called the tunica vaginalis testis. The tunica serosa uteri covers the internal reproductive organs in women.

2. What is mesothelioma?

Mesothelioma (cancer of the mesothelium) is a disease in which cells of the mesothelium become abnormal and divide without control or order. They can invade and damage nearby tissues and organs. Cancer cells can also metastasize (spread) from their original site to other parts of the body. Most cases of mesothelioma begin in the pleura or peritoneum.

3. How common is mesothelioma?

Although reported incidence rates have increased in the past 20 years, mesothelioma is still a relatively rare cancer. About 2,000 new cases of mesothelioma are diagnosed in the United States each year. Mesothelioma occurs more often in men than in women and risk increases with age, but this disease can appear in either men or women at any age.

4. What are the risk factors for mesothelioma?

Working with asbestos is the major risk factor for mesothelioma. A history of asbestos exposure at work is reported in about 70 percent to 80 percent of all cases. However, mesothelioma has been reported in some individuals without any known exposure to asbestos.

Asbestos is the name of a group of minerals that occur naturally as masses of strong, flexible fibers that can be separated into thin threads and woven. Asbestos has been widely used in many industrial products, including cement, brake linings, roof shingles, flooring products, textiles, and insulation. If tiny asbestos particles float in the air, especially during the manufacturing process, they may be inhaled or swallowed, and can cause serious health problems. In addition to mesothelioma, exposure to asbestos increases the risk of lung cancer, asbestosis (a noncancerous, chronic lung ailment), and other cancers, such as those of the larynx and kidney.

Smoking does not appear to increase the risk of mesothelioma. However, the combination of smoking and asbestos exposure significantly increases a person’s risk of developing cancer of the air passageways in the lung.

5. Who is at increased risk for developing mesothelioma?

Asbestos has been mined and used commercially since the late 1800s. Its use greatly increased during World War II. Since the early 1940s, millions of American workers have been exposed to asbestos dust. Initially, the risks associated with asbestos exposure were not known. However, an increased risk of developing mesothelioma was later found among shipyard workers, people who work in asbestos mines and mills, producers of asbestos products, workers in the heating and construction industries, and other tradespeople. Today, the U.S. Occupational Safety and Health Administration (OSHA) sets limits for acceptable levels of asbestos exposure in the workplace. People who work with asbestos wear personal protective equipment to lower their risk of exposure.

The risk of asbestos-related disease increases with heavier exposure to asbestos and longer exposure time. However, some individuals with only brief exposures have developed mesothelioma. On the other hand, not all workers who are heavily exposed develop asbestos-related diseases.

There is some evidence that family members and others living with asbestos workers have an increased risk of developing mesothelioma, and possibly other asbestos-related diseases. This risk may be the result of exposure to asbestos dust brought home on the clothing and hair of asbestos workers. To reduce the chance of exposing family members to asbestos fibers, asbestos workers are usually required to shower and change their clothing before leaving the workplace.

6. What are the symptoms of mesothelioma?

Symptoms of mesothelioma may not appear until 30 to 50 years after exposure to asbestos. Shortness of breath and pain in the chest due to an accumulation of fluid in the pleura are often symptoms of pleural mesothelioma. Symptoms of peritoneal mesothelioma include weight loss and abdominal pain and swelling due to a buildup of fluid in the abdomen. Other symptoms of peritoneal mesothelioma may include bowel obstruction, blood clotting abnormalities, anemia, and fever. If the cancer has spread beyond the mesothelium to other parts of the body, symptoms may include pain, trouble swallowing, or swelling of the neck or face.

These symptoms may be caused by mesothelioma or by other, less serious conditions. It is important to see a doctor about any of these symptoms. Only a doctor can make a diagnosis.

7. How is mesothelioma diagnosed?

Diagnosing mesothelioma is often difficult, because the symptoms are similar to those of a number of other conditions. Diagnosis begins with a review of the patient’s medical history, including any history of asbestos exposure. A complete physical examination may be performed, including x-rays of the chest or abdomen and lung function tests. A CT (or CAT) scan or an MRI may also be useful. A CT scan is a series of detailed pictures of areas inside the body created by a computer linked to an x-ray machine. In an MRI, a powerful magnet linked to a computer is used to make detailed pictures of areas inside the body. These pictures are viewed on a monitor and can also be printed.

A biopsy is needed to confirm a diagnosis of mesothelioma. In a biopsy, a surgeon or a medical oncologist (a doctor who specializes in diagnosing and treating cancer) removes a sample of tissue for examination under a microscope by a pathologist. A biopsy may be done in different ways, depending on where the abnormal area is located. If the cancer is in the chest, the doctor may perform a thoracoscopy. In this procedure, the doctor makes a small cut through the chest wall and puts a thin, lighted tube called a thoracoscope into the chest between two ribs. Thoracoscopy allows the doctor to look inside the chest and obtain tissue samples. If the cancer is in the abdomen, the doctor may perform a peritoneoscopy. To obtain tissue for examination, the doctor makes a small opening in the abdomen and inserts a special instrument called a peritoneoscope into the abdominal cavity. If these procedures do not yield enough tissue, more extensive diagnostic surgery may be necessary.

If the diagnosis is mesothelioma, the doctor will want to learn the stage (or extent) of the disease. Staging involves more tests in a careful attempt to find out whether the cancer has spread and, if so, to which parts of the body. Knowing the stage of the disease helps the doctor plan treatment.

Mesothelioma is described as localized if the cancer is found only on the membrane surface where it originated. It is classified as advanced if it has spread beyond the original membrane surface to other parts of the body, such as the lymph nodes, lungs, chest wall, or abdominal organs.

8. How is mesothelioma treated?
   • Surgery is a common treatment for mesothelioma. The doctor may remove part of the lining of the chest or abdomen and some of the tissue around it. For cancer of the pleura (pleural mesothelioma), a lung may be removed in an operation called a pneumonectomy. Sometimes part of the diaphragm, the muscle below the lungs that helps with breathing, is also removed.
   • Radiation therapy, also called radiotherapy, involves the use of high-energy rays to kill cancer cells and shrink tumors. Radiation therapy affects the cancer cells only in the treated area. The radiation may come from a machine (external radiation) or from putting materials that produce radiation through thin plastic tubes into the area where the cancer cells are found (internal radiation therapy).
   • Chemotherapy is the use of anticancer drugs to kill cancer cells throughout the body. Most drugs used to treat mesothelioma are given by injection into a vein (intravenous, or IV). Doctors are also studying the effectiveness of putting chemotherapy directly into the chest or abdomen (intracavitary chemotherapy).

Treatment for mesothelioma depends on the location of the cancer, the stage of the disease, and the patient’s age and general health. Standard treatment options include surgery, radiation therapy, and chemotherapy. Sometimes, these treatments are combined.

To relieve symptoms and control pain, the doctor may use a needle or a thin tube to drain fluid that has built up in the chest or abdomen. The procedure for removing fluid from the chest is called thoracentesis. Removal of fluid from the abdomen is called paracentesis. Drugs may be given through a tube in the chest to prevent more fluid from accumulating. Radiation therapy and surgery may also be helpful in relieving symptoms.

9. Are new treatments for mesothelioma being studied?

Yes. Because mesothelioma is very hard to control, the National Cancer Institute (NCI) is sponsoring clinical trials (research studies with people) that are designed to find new treatments and better ways to use current treatments. Before any new treatment can be recommended for general use, doctors conduct clinical trials to find out whether the treatment is safe for patients and effective against the disease. Participation in clinical trials is an important treatment option for many patients with mesothelioma.

People interested in taking part in a clinical trial should talk with their doctor. Information about clinical trials is available from the Cancer Information Service (CIS) (see below) at 1–800–4–CANCER. Information specialists at the CIS use PDQ®, NCI’s cancer information database, to identify and provide detailed information about specific ongoing clinical trials. Patients also have the option of searching for clinical trials on their own. The clinical trials page on the NCI’s Cancer.gov Web site, located at http://www.cancer.gov/clinical_trials on the Internet, provides general information about clinical trials and links to PDQ.

People considering clinical trials may be interested in the NCI booklet Taking Part in Clinical Trials: What Cancer Patients Need To Know. This booklet describes how research studies are carried out and explains their possible benefits and risks. The booklet is available by calling the CIS, or from the NCI Publications Locator Web site at http://www.cancer.gov/publications on the Internet.

Cancer Information Service (toll-free)

Telephone: 1–800–4–CANCER (1–800–422–6237)
TTY: 1–800–332–8615

Online

NCI’s Web site: http://www.cancer.gov
LiveHelp, NCI’s live online assistance:
https://cissecure.nci.nih.gov/livehelp/welcome.asp

 

 

# # #

National Cancer Institute (NCI) Resources

 

Telmisartan, a drug widely used to help control blood pressure, may have uniquely potent activity in preventing stroke, according to a new study conducted in an animal model.Whether they used the drug alone or in combination with a different type of antihypertensive medication, ramipril, Weill Cornell Medical College researchers found that rats fed a high-salt, stroke-inducing diet were completely protected from the brain attacks while on telmisartan.

“No other study has ever shown complete protection against stroke in this rat model using normal human drug doses” notes study senior author Dr. Daniel F. Catanzaro, professor of physiology and biophysics and professor of physiology in cardiothoracic surgery at Weill Cornell Medical College.

The study, which was funded by telmisartan’s German maker, Boehringer Ingelheim Pharma GmbH & Co., is published online in the Journal of the American Society of Hypertension.

Telmisartan (brand name Micardis) is one of a class of widely used antihypertensive drugs known as angiotensin receptor blockers (ARBs). “These drugs primarily act on the vasculature to relax the small blood vessels,” Dr. Catanzaro explains.

Telmisartan stands out from other ARBs in that its molecular structure allows it to more easily pass through the blood-brain barrier and enter the brain—something many drugs cannot do.

The new animal study was not constructed to specifically look at telmisartan’s effect on stroke. “Because blood pressure is closely related to stroke risk, we really just wanted to look and see if combinations of antihypertensive drugs were better at lowering blood pressure and stroke compared to the use of single agents,” Dr. Catanzaro explains.

In this case, his team tested two drugs—telmisartan and an ACE inhibitor, ramipril (Altace)—in a rat model long favored by stroke researchers. In this approach, rats are fed what’s known as a “stroke-prone diet,” meaning they get lots of salt in both their food and water.

“This rat model has been great at showing us the neuroprotective properties of different drugs in the past, and the results usually correlate with results in humans,” Dr. Catanzaro says.

In the study, 25 rats were fed the stroke-prone diet for 8 weeks and received either no medication, telmisartan alone, ramipril alone, or the two drugs together at either full- or half-doses.

“A main finding was that combination therapy did reduce blood pressure the best of any treatment, and it also was best at cutting damage to the rats’ hearts and kidneys,” Dr. Catanzaro says. “But what was really surprising to us was that any regimen involving telmisartan at doses that would normally be given to humans completely prevented stroke in this model. Most studies with other drugs have used much higher doses and have found only partial protection.”

Specifically, 83 percent of rats given no medication showed signs of stroke, as did 56 percent of rats given ramipril alone. However, no strokes were noted in the telmisartan-only or the telmisartan/ramipril combo groups.

Telmisartan’s ability to easily pass through the blood-brain barrier (something ramipril cannot do) is likely behind the neuroprotective effect noted in the study, the researchers say.

“Going forward, that’s something that we would really like to test out in head-to-head trials pitting telmisartan against other ARBs, for example,” Dr. Catanzaro said. “At the same time, we’d like to examine whether telmisartan is actually getting into the brain, or if more peripheral effects—a lowering of blood pressure, for instance—are behind the reduction in stroke.”

In the meantime, Boehringer Ingelheim is nearing the end of a major clinical trial looking at the effectiveness of combining telmisartan with ramipril to lower patients’ blood pressures and reduce their odds for heart attack and stroke. Dr. Catanzaro’s team is not involved in that study.

Co-authors on this study include lead researcher Dr. Ying Zhou, as well as Dr. Fangmin Yu and Dr. Ada R. Ene—all of Weill Cornell Medical College in New York City.

Adapted from materials provided by Weill Cornell Medical Center.

A company, based in Rockville, Maryland in the USA, with the help of government funding, has used the human genome to develop a vaccine that may give protection from anthrax.(original article)

AIDS Healthcare Foundation (AHF) today strongly criticized Ryan White CARE Act funding levels contained in the latest budget package drafted by Congress in order to meet the restrictions of President George W. Bush’s spending target for next year.(original article)

A new biochip technology could eliminate animal testing in the chemicals and cosmetics industries, and drastically curtail its use in the development of new pharmaceuticals, according to new findings from a team of researchers at Rensselaer Polytechnic Institute, the University of California at Berkeley, and Solidus Biosciences Inc.(original article)

Chalmers University of technology in Sweden is about to enter a new field of research - biological physics.(original article)